Entero Healthcare Solutions Ltd
ENTERO NSE
Entero Healthcare Solutions Ltd
RetailNSE: ENTERO BSE: 544122 Pharmacy Retail
Key Fundamentals
MicrocapPharmacy RetailRetailMarket Cap
₹6,053 Cr
Volatility
Moderate
P/E Ratio
48.86
EBITDA
₹285 Cr
Return on Equity
8.32%
Debt to Equity
0.4
Book Value
₹386.51
EPS
₹8.99
52W High
₹1,467.8
52W Low
₹944
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Entero Healthcare Solutions Ltd insights
47 extracted metrics + investor summaries across FY20–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company is expected to give good quarter
- Company has delivered good profit growth of 57.3% CAGR over last 5 years
- Company's working capital requirements have reduced from 49.4 days to 34.8 days
Weaknesses
3- Stock is trading at 3.63 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 6.04% over last 3 years.
Growth Rate
Revenue Growth
28.72% ↗
Net Income Growth
35.75% ↗
Cash Flow Change
225.15% ↗
ROE
37.07% ↗
ROCE
19.57% ↗
EBITDA Margin (Avg.)
4.87% ↘
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 43d agoAI opinion · based on fundamentals
Risk medium
Entero Healthcare Solutions is a pharmaceutical distribution company with a market cap of ~₹5,269 Cr trading at a P/E of 36.2x. The company has grown consolidated revenue from ₹2,522 Cr in FY22 to ₹6,591 Cr in FY26 (a 30% 5-year sales CAGR), while net profit rose from a loss to ₹146 Cr in FY26. However, operating margins remain thin at ~4% and return on equity is modest at around 6-7%.
Bull Case 8
- Strong revenue growth with 5-year compounded sales CAGR of 30%, reaching ₹6,591 Cr in FY26 from ₹2,522 Cr in FY22
- Net profit grew from a loss of ₹29 Cr in FY22 to ₹146 Cr in FY26, reflecting a 57.5% profit CAGR over 5 years
- FY26 full-year revenue grew 31.5% YoY on a like-for-like basis, indicating continued momentum
- Operating profit margin expanding from 0.97% in FY22 to 4.02% in FY26, showing improving operational leverage
- Q4 FY26 net profit of ₹45 Cr showed 43.6% YoY growth, suggesting acceleration in recent quarters
- Debt-to-equity ratio at 0.34x indicates a relatively conservative balance sheet for a distribution business
- TTM profit growth of 26% shows earnings momentum is sustained even on a larger base
- EBITDA grew from ₹29 Cr in FY22 to ₹285 Cr in FY26, a nearly 10x increase over four years
Bear Case 8
- Return on equity is low at 6.07% over the last 3 years and only 7% in the latest year, weak for a company trading at 3.13x book value
- Net profit margin remains very thin at just 2.2% in FY26 (PAT of ₹146 Cr on revenue of ₹6,591 Cr), typical of distribution but vulnerable to cost shocks
- P/E of 36.2x is expensive relative to the modest ROE of 6-7%, implying the market is pricing in significant future improvement
- Zero dividend payout despite reporting consecutive years of profit, offering no income return to shareholders
- Stock has delivered -2% CAGR over 1 year, underperforming despite strong underlying profit growth
- Interest costs rose from ₹29 Cr in FY22 to ₹54 Cr in FY26, reflecting growing working capital needs inherent to the distribution model
- Operating in a low-margin pharmaceutical distribution business where pricing power is structurally limited
- Trading at 3.13x book value while generating only 7% ROE means the valuation premium is not yet justified by capital efficiency
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 43d ago Headwinds 1
- Nominee director resigns Jun 12
Kevin Rohitbhai Daftary resigned as Nominee Director effective June 12, 2026, citing increased professional commitments. Loss of board representation from a nominee could signal reduced investor oversight.
Positives 1
- ESOP allotment signals retention Jun 26
Entero Healthcare allotted 1,475 equity shares under ESOP 2023 and reappointed two independent directors for a second term. This indicates management stability and employee retention efforts.
Neutral 1
- Trading window closed for Q1FY27 Jun 23
Trading window shuts from July 1, 2026, until 48 hours after Q1FY27 results are declared. This is a routine pre-results compliance measure.
TL;DR: A quiet period for Entero Healthcare with no material operational or financial news. Routine corporate governance actions like ESOP allotments and director reappointments suggest stability, while the nominee director resignation is a minor governance watch item. No clear directional catalyst is visible; the near-term outlook depends on Q1FY27 results expected in the coming weeks.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 899 | 996 | 993 | 1,034 | 1,097 | 1,301 | 1,359 | 1,339 | 1,404 | 1,571 | 1,707 | 1,910 | 1,940 |
| Expenses | 873 | 968 | 964 | 1,005 | 1,067 | 1,258 | 1,309 | 1,290 | 1,354 | 1,509 | 1,639 | 1,824 | 1,844 |
| Operating Profit | 26 | 29 | 29 | 29 | 30 | 42 | 50 | 49 | 50 | 62 | 68 | 86 | 97 |
| OPM % | 2.9% | 2.9% | 2.9% | 2.8% | 2.8% | 3.3% | 3.7% | 3.6% | 3.6% | 4% | 4% | 4.5% | 5% |
| Other Income | 1 | 2 | 2 | 9 | 13 | 11 | 8 | 7 | 6 | 5 | -4 | 4 | 3 |
| Interest | 14 | 18 | 16 | 17 | 10 | 11 | 10 | 10 | 11 | 12 | 14 | 17 | 21 |
| Depreciation | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 | 10 | 10 | 15 | 12 |
| PBT | 7 | 7 | 8 | 14 | 27 | 35 | 39 | 37 | 36 | 45 | 40 | 58 | 67 |
| Tax % | 6% | 23% | 16% | -56% | 25% | 25% | 25% | 16% | 17% | 18% | 16% | 22% | 22% |
| Net Profit | 6 | 5 | 7 | 21 | 21 | 26 | 29 | 31 | 30 | 37 | 34 | 45 | 52 |
| EPS in Rs | 15.18 | 3.19 | 4.22 | 4.82 | 4.62 | 5.43 | 5.85 | 5.9 | 6.39 | 7.26 | 6.35 | 6.44 | 8.77 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,350 | 1,773 | 2,522 | 3,300 | 3,922 | 5,096 | 6,591 | 7,128 |
| Expenses | 1,326 | 1,758 | 2,498 | 3,236 | 3,810 | 4,924 | 6,325 | 6,815 |
| Operating Profit | 23 | 15 | 24 | 64 | 112 | 172 | 266 | 313 |
| OPM % | 1.7% | 0.8% | 1% | 1.9% | 2.9% | 3.4% | 4% | 4.4% |
| Other Income | 5 | 11 | 4 | 6 | 14 | 39 | 11 | 8 |
| Interest | 13 | 20 | 29 | 49 | 66 | 42 | 54 | 64 |
| Depreciation | 12 | 16 | 20 | 24 | 25 | 31 | 43 | 47 |
| PBT | 4 | -11 | -20 | -4 | 36 | 139 | 179 | 210 |
| Tax % | 67% | 42% | 49% | 201% | -12% | 23% | 19% | — |
| Net Profit | 1 | -15 | -29 | -11 | 40 | 107 | 146 | 168 |
| EPS in Rs | 93.81 | -1,551 | -77.71 | -28.12 | 8.99 | 21.79 | 26.44 | 28.82 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.1 | 0.1 | 4 | 4 | 43 | 44 | 44 |
| Reserves | -16 | -32 | -62 | -73 | 1,595 | 1,681 | 1,645 |
| Borrowings | 603 | 720 | 974 | 1,101 | 338 | 385 | 677 |
| Other Liabilities | 162 | 147 | 210 | 275 | 369 | 593 | 1,234 |
| Total Liabilities | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 3,600 |
| Fixed Assets | 186 | 189 | 262 | 268 | 289 | 559 | 958 |
| CWIP | 2 | 2 | 1 | 0 | 0 | 0 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 58 | 130 |
| Other Assets | 560 | 645 | 863 | 1,040 | 2,056 | 2,085 | 2,510 |
| Total Assets | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 3,600 |
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Operating | -37 | -69 | -35 | -45 | -37 | -77 | 96 |
| Investing | -203 | -31 | -162 | -49 | -704 | 232 | -302 |
| Financing | 217 | 89 | 211 | 73 | 863 | -74 | 124 |
| Net Cash Flow | -23 | -11 | 14 | -21 | 122 | 82 | -82 |
| Free Cash Flow | -81 | -78 | -45 | -51 | -41 | -87 | 29 |
| CFO/OP | -134 | -430 | -100 | -51 | -21 | -23 | 56 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 63 | 50 | 54 | 57 | 57 | 59 | 67 |
| Inventory Days | 57 | 54 | 49 | 41 | 43 | 52 | 52 |
| Days Payable | 32 | 22 | 22 | 25 | 24 | 31 | 45 |
| Cash Conversion Cycle | 88 | 82 | 81 | 73 | 77 | 80 | 74 |
| Working Capital Days | 57 | 54 | 41 | 32 | 48 | 65 | 35 |
| ROCE % | — | 1% | 1% | 5% | 7% | 9% | 10% |
Documents
1
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
6 May - MCA approved fast-track merger of two subsidiaries into Rada Medisolutions, effective 15 April 2025. 6 May - MCA approved fast-track merger of two subsidiaries into Rada Medisolutions, effective 15 April 2025.
2
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Certificate u/r 74(5) of SEBI(DP) Regulations, 2018 for the quarter ended March 31, 2026 8 Apr - Certificate u/r 74(5) of SEBI(DP) Regulations, 2018 for the quarter ended March 31, 2026
4
Announcement under Regulation 30 (LODR)-Change in Management
11 Mar - Sambit Mohanty resigns as President—Institutional Business; ceases SMP effective close of business March 31, 2026. 11 Mar - Sambit Mohanty resigns as President—Institutional Business; ceases SMP effective close of business March 31, 2026.
5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
26 Feb - Of Schedule of Analyst/Institutional Investor meet to be held on March 06, 2026 26 Feb - Of Schedule of Analyst/Institutional Investor meet to be held on March 06, 2026
Frequently Asked Questions about Entero Healthcare Solutions Ltd
What does Entero Healthcare Solutions Ltd do?
Incorporated in 2018, Entero Healthcare
Solutions Ltd is in the business of distribution
and marketing of pharmaceutical and surgical products and allied services[1]
Where is Entero Healthcare Solutions Ltd (ENTERO) listed?
Entero Healthcare Solutions Ltd is listed on the Indian stock exchanges. It is listed on NSE: ENTERO and BSE: 544122. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Entero Healthcare Solutions Ltd belong to?
Entero Healthcare Solutions Ltd operates in the Retail sector within the Pharmacy Retail industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Entero Healthcare Solutions Ltd?
Entero Healthcare Solutions Ltd has a market capitalisation of approximately ₹6052.94 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Entero Healthcare Solutions Ltd?
The Price-to-Earnings (PE) ratio of Entero Healthcare Solutions Ltd is 48.86. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Entero Healthcare Solutions Ltd?
Over the past 52 weeks, Entero Healthcare Solutions Ltd has traded between a low of ₹944 and a high of ₹1,467.8. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Entero Healthcare Solutions Ltd?
Entero Healthcare Solutions Ltd has a Return on Equity (ROE) of 8.32%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Entero Healthcare Solutions Ltd on Tapetide?
On Tapetide, you can view Entero Healthcare Solutions Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2018, Entero Healthcare Solutions Ltd is in the business of distribution and marketing of pharmaceutical and surgical products and allied services[1]
Website enterohealthcare.com
CEO Mr. Prabhat Agrawal
Employees 4,111
Listed 2024-02-16
Face Value ₹ 10
Issued Size 4,35,10,937